Wegovy Side Effects: Complete FDA Safety Guide
Wegovy (semaglutide) is FDA-approved for chronic weight management and cardiovascular risk reduction in adults with established CVD and obesity. The most common side effects are gastrointestinal, nausea, diarrhoea, vomiting, constipation, and the most serious are pancreatitis, gallbladder disease, kidney injury, hypoglycaemia with insulin, and a boxed warning about thyroid C-cell tumours.
Wegovy (Semaglutide) is approved as a Glucagon-like peptide-1 (GLP-1) receptor agonist. Most common side effects are gastrointestinal (nausea, vomiting, diarrhoea, constipation). Serious risks include pancreatitis, kidney injury, gallbladder disease and hypoglycaemia with insulin. It carries an FDA boxed warning for thyroid C-cell tumours.
Key Takeaways
- Wegovy carries a boxed warning for thyroid C-cell tumours, contraindicated if personal or family history of medullary thyroid carcinoma or MEN2.
- Most common side effects: nausea, diarrhoea, vomiting, constipation, abdominal pain, headache, fatigue.
- Major label warnings: pancreatitis, acute kidney injury, gallbladder disease, severe hypoglycaemia with insulin/sulfonylureas, hypersensitivity, suicidal behaviour and ideation (monitor mood), retinopathy worsening in T2D.
- Alcohol can worsen nausea and dehydration; combine carefully if also on glucose-lowering medicines, read more.
- Disclose Wegovy use to your anaesthetist before any procedure due to delayed gastric emptying and aspiration risk.
- Check Wegovy against your full medication list with the Allmeds drug interaction checker.
What is Wegovy, and what is it used for?
Wegovy is a once-weekly injectable semaglutide approved for chronic weight management and for cardiovascular risk reduction in adults with established CVD and obesity.
| Property | Detail |
|---|---|
| Generic name | Semaglutide |
| Brand names | Wegovy (weight management), Ozempic (T2D), Rybelsus (oral) |
| Drug class | GLP-1 receptor agonist |
| FDA approval status | Approved, chronic weight management; CV risk reduction in adults with CVD and obesity |
| Route | Subcutaneous injection, once weekly |
| Boxed warning | Thyroid C-cell tumours (animal data) |
| Common GI side effects | Nausea, diarrhoea, vomiting, constipation, abdominal pain, headache, fatigue |
| Major label warnings | Pancreatitis, kidney injury, gallbladder disease, hypoglycaemia, suicidal ideation, retinopathy |
What are the side effects of Wegovy?
The FDA prescribing information for Wegovy groups side effects into common gastrointestinal symptoms (very frequent at initiation and dose escalation) and serious warnings (less frequent but clinically important). The table below summarises the labelled categories with severity colour-coding.
| Side Effect Category | What May Occur | Why It Matters |
|---|---|---|
| Pancreatitis | Severe, persistent abdominal pain (sometimes radiating to the back), nausea, vomiting | All GLP-1 labels warn about acute pancreatitis. Stop the medicine and seek urgent assessment. |
| Thyroid C-cell tumours (boxed warning) | Neck mass, hoarseness, difficulty swallowing, persistent neck pain | Animal studies show medullary thyroid carcinoma risk. Contraindicated if personal or family history of MTC or MEN2. |
| Acute kidney injury | Reduced urine output, swelling, fatigue, usually after vomiting or diarrhoea | Dehydration from GI side effects can precipitate AKI, particularly in patients with prior renal disease. |
| Severe hypoglycaemia | Sweating, shakiness, confusion, palpitations, seizure, loss of consciousness | Risk rises sharply when combined with insulin or sulfonylureas. Dose reduction of the other glucose-lowering drug is usually required. |
| Gallbladder disease | Right-upper abdominal pain, fever, jaundice | Cholelithiasis and cholecystitis are reported, especially with rapid weight loss. |
| Severe gastrointestinal reactions | Persistent nausea, vomiting, diarrhoea, constipation, abdominal pain | Common and dose-dependent. Most pronounced during initiation and dose escalation. |
| Diabetic retinopathy worsening | Blurred vision, vision changes | Rapid glucose lowering has been associated with transient worsening, relevant in long-standing type 2 diabetes. |
| Hypersensitivity reactions | Rash, urticaria, angioedema, anaphylaxis | Stop the medicine and seek urgent care for serious allergic features. |
| Injection-site reactions | Redness, swelling, itching, induration at the injection site | Usually mild; persistent reactions warrant clinical review. |
| Aspiration risk during anaesthesia | Delayed gastric emptying may leave food in the stomach during sedation | Disclose GLP-1 use to your anaesthetist before any procedure or surgery. |
Taking Wegovy alongside other medications?
Check Wegovy against your full medication list instantly. Allmeds scans the widest drug interaction database in minutes.
How does Wegovy work, and why does that drive the side effects?
Semaglutide mimics GLP-1, suppressing appetite and slowing gastric emptying. At Wegovy weight-management doses (higher than Ozempic), GI side effects and the gallbladder/pancreatitis risks are more pronounced. The cardiovascular benefit (SELECT trial) is part of the labelled indication.
Can you drink alcohol while taking Wegovy?
Alcohol is not contraindicated, but it worsens nausea, dehydration, and pancreatitis risk during rapid weight loss.
Symptoms and when to seek care
Seek urgent medical assessment if you experience any of the following while taking Wegovy:
- Severe, persistent abdominal pain (possible pancreatitis)
- Sudden swelling of the face, lips, tongue or throat, or difficulty breathing (allergic reaction)
- Right-upper abdominal pain with fever or jaundice (gallbladder disease)
- Severe vomiting or diarrhoea with reduced urine output (dehydration / kidney injury)
- Severe hypoglycaemia, sweating, confusion, palpitations, loss of consciousness (especially if also on insulin or sulfonylurea)
- New neck mass, hoarseness, or difficulty swallowing (thyroid concern)
- New or worsening depression, mood changes, or suicidal thoughts (Wegovy/Zepbound)
Common Questions About Wegovy Side Effects
Nausea, diarrhoea, vomiting, constipation, abdominal pain, headache, and fatigue. Most are dose-dependent and improve over time. Severe or persistent symptoms warrant clinical review.
Both are semaglutide. Wegovy is dosed higher for weight management, so GI side effects and gallbladder risks tend to be more prominent. The same boxed warning and major warnings apply.
Wegovy carries an FDA boxed warning for thyroid C-cell tumours, based on rodent studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
Hair loss has been reported, generally during rapid weight loss rather than as a direct drug effect. It is usually reversible with slower weight reduction and adequate nutrition.
Discuss with your prescriber and anaesthetist. Semaglutide slows gastric emptying, which can leave food in the stomach during sedation and create aspiration risk. Many anaesthetic services now pause GLP-1 medicines before elective procedures.
References
- U.S. Food & Drug Administration. Ozempic (semaglutide) prescribing information. fda.gov.
- U.S. Food & Drug Administration. Wegovy (semaglutide) prescribing information. fda.gov.
- U.S. Food & Drug Administration. Mounjaro (tirzepatide) prescribing information. fda.gov.
- U.S. Food & Drug Administration. Zepbound (tirzepatide) prescribing information. fda.gov.
- European Medicines Agency. Ozempic, Wegovy, Mounjaro, EPAR product information. ema.europa.eu.
- Therapeutic Goods Administration (Australia). Australian Register of Therapeutic Goods (ARTG). tga.gov.au.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
Check Wegovy against your full medication list
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile, in minutes.